Cargando…

Pneumococcal vaccination coverage in individuals (16–59 years) with a newly diagnosed risk condition in Germany

BACKGROUND: Despite recommendations from the German Standing Committee on Vaccination (STIKO), pneumococcal vaccination coverage remains low in vulnerable populations. This study estimated the pneumococcal vaccination coverage rate (VCR) and timing among individuals aged 16–59 years in Germany who w...

Descripción completa

Detalles Bibliográficos
Autores principales: Deb, Arijita, Podmore, Bélène, Barnett, Rosemarie, Beier, Dominik, Galetzka, Wolfgang, Qizilbash, Nawab, Haeckl, Dennis, Boellinger, Timo, Johnson, Kelly D., Weiss, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9517976/
https://www.ncbi.nlm.nih.gov/pubmed/36171549
http://dx.doi.org/10.1186/s12879-022-07736-1
_version_ 1784799071508103168
author Deb, Arijita
Podmore, Bélène
Barnett, Rosemarie
Beier, Dominik
Galetzka, Wolfgang
Qizilbash, Nawab
Haeckl, Dennis
Boellinger, Timo
Johnson, Kelly D.
Weiss, Thomas
author_facet Deb, Arijita
Podmore, Bélène
Barnett, Rosemarie
Beier, Dominik
Galetzka, Wolfgang
Qizilbash, Nawab
Haeckl, Dennis
Boellinger, Timo
Johnson, Kelly D.
Weiss, Thomas
author_sort Deb, Arijita
collection PubMed
description BACKGROUND: Despite recommendations from the German Standing Committee on Vaccination (STIKO), pneumococcal vaccination coverage remains low in vulnerable populations. This study estimated the pneumococcal vaccination coverage rate (VCR) and timing among individuals aged 16–59 years in Germany who were recommended to receive pneumococcal vaccination, according to STIKO. METHODS: A retrospective cohort analysis was conducted using the German InGef database. Individuals aged 16 to 59 years diagnosed with at least one “at-risk” (chronic disease) or “high-risk” (e.g., immunocompromising) condition considered to be at-risk of pneumococcal infection were identified at the time of first diagnosis, between January 1, 2016 and December 31, 2018, and followed up until December 31, 2019. The percentage of cumulative pneumococcal VCR with 95% confidence interval (CI) was reported for each calendar year of follow-up. RESULTS: There were 334,292 individuals followed for a median of 2.38 (interquartile range (IQR) 1.63–3.13) person years. For individuals aged 16–59 years diagnosed with an incident risk condition in 2016, pneumococcal VCR increased from 0.44% (95% CI 0.41–0.48) in 2016 to 1.24% (95% CI 1.18–1.30) in 2019. In 2019, VCRs were higher in individuals with high-risk conditions compared with at-risk conditions (2.24% (95% CI 2.09–2.40) vs. 0.90% (95% CI 0.85–0.96)). In 2019, VCRs were higher in individuals aged 50 to 59 years compared with individuals aged 16 to 49 years (2.25% (95% CI 2.10–2.41) vs. 0.90% (95% CI 0.84–0.96)). Similar trends were observed in individuals with newly diagnosed risk conditions identified in 2017 and in 2018. Older age, influenza vaccination and increasing number of risk conditions increased the likelihood of pneumococcal vaccination. Median time to vaccination from diagnosis of the risk condition was shorter for high-risk conditions (369.5 days (IQR 155.8–702.0)) compared to at-risk conditions (435.5 days (IQR 196.3–758.8)). CONCLUSION: Despite recommendations from STIKO, pneumococcal vaccination coverage remains very low and with long delays in vulnerable individuals aged 16–59 in Germany. Further efforts are required to increase immunization levels and shorten time to vaccination among individuals 16–59 years of age developing conditions with higher susceptibility to pneumococcal infection. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-022-07736-1.
format Online
Article
Text
id pubmed-9517976
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-95179762022-09-29 Pneumococcal vaccination coverage in individuals (16–59 years) with a newly diagnosed risk condition in Germany Deb, Arijita Podmore, Bélène Barnett, Rosemarie Beier, Dominik Galetzka, Wolfgang Qizilbash, Nawab Haeckl, Dennis Boellinger, Timo Johnson, Kelly D. Weiss, Thomas BMC Infect Dis Research BACKGROUND: Despite recommendations from the German Standing Committee on Vaccination (STIKO), pneumococcal vaccination coverage remains low in vulnerable populations. This study estimated the pneumococcal vaccination coverage rate (VCR) and timing among individuals aged 16–59 years in Germany who were recommended to receive pneumococcal vaccination, according to STIKO. METHODS: A retrospective cohort analysis was conducted using the German InGef database. Individuals aged 16 to 59 years diagnosed with at least one “at-risk” (chronic disease) or “high-risk” (e.g., immunocompromising) condition considered to be at-risk of pneumococcal infection were identified at the time of first diagnosis, between January 1, 2016 and December 31, 2018, and followed up until December 31, 2019. The percentage of cumulative pneumococcal VCR with 95% confidence interval (CI) was reported for each calendar year of follow-up. RESULTS: There were 334,292 individuals followed for a median of 2.38 (interquartile range (IQR) 1.63–3.13) person years. For individuals aged 16–59 years diagnosed with an incident risk condition in 2016, pneumococcal VCR increased from 0.44% (95% CI 0.41–0.48) in 2016 to 1.24% (95% CI 1.18–1.30) in 2019. In 2019, VCRs were higher in individuals with high-risk conditions compared with at-risk conditions (2.24% (95% CI 2.09–2.40) vs. 0.90% (95% CI 0.85–0.96)). In 2019, VCRs were higher in individuals aged 50 to 59 years compared with individuals aged 16 to 49 years (2.25% (95% CI 2.10–2.41) vs. 0.90% (95% CI 0.84–0.96)). Similar trends were observed in individuals with newly diagnosed risk conditions identified in 2017 and in 2018. Older age, influenza vaccination and increasing number of risk conditions increased the likelihood of pneumococcal vaccination. Median time to vaccination from diagnosis of the risk condition was shorter for high-risk conditions (369.5 days (IQR 155.8–702.0)) compared to at-risk conditions (435.5 days (IQR 196.3–758.8)). CONCLUSION: Despite recommendations from STIKO, pneumococcal vaccination coverage remains very low and with long delays in vulnerable individuals aged 16–59 in Germany. Further efforts are required to increase immunization levels and shorten time to vaccination among individuals 16–59 years of age developing conditions with higher susceptibility to pneumococcal infection. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-022-07736-1. BioMed Central 2022-09-28 /pmc/articles/PMC9517976/ /pubmed/36171549 http://dx.doi.org/10.1186/s12879-022-07736-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Deb, Arijita
Podmore, Bélène
Barnett, Rosemarie
Beier, Dominik
Galetzka, Wolfgang
Qizilbash, Nawab
Haeckl, Dennis
Boellinger, Timo
Johnson, Kelly D.
Weiss, Thomas
Pneumococcal vaccination coverage in individuals (16–59 years) with a newly diagnosed risk condition in Germany
title Pneumococcal vaccination coverage in individuals (16–59 years) with a newly diagnosed risk condition in Germany
title_full Pneumococcal vaccination coverage in individuals (16–59 years) with a newly diagnosed risk condition in Germany
title_fullStr Pneumococcal vaccination coverage in individuals (16–59 years) with a newly diagnosed risk condition in Germany
title_full_unstemmed Pneumococcal vaccination coverage in individuals (16–59 years) with a newly diagnosed risk condition in Germany
title_short Pneumococcal vaccination coverage in individuals (16–59 years) with a newly diagnosed risk condition in Germany
title_sort pneumococcal vaccination coverage in individuals (16–59 years) with a newly diagnosed risk condition in germany
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9517976/
https://www.ncbi.nlm.nih.gov/pubmed/36171549
http://dx.doi.org/10.1186/s12879-022-07736-1
work_keys_str_mv AT debarijita pneumococcalvaccinationcoverageinindividuals1659yearswithanewlydiagnosedriskconditioningermany
AT podmorebelene pneumococcalvaccinationcoverageinindividuals1659yearswithanewlydiagnosedriskconditioningermany
AT barnettrosemarie pneumococcalvaccinationcoverageinindividuals1659yearswithanewlydiagnosedriskconditioningermany
AT beierdominik pneumococcalvaccinationcoverageinindividuals1659yearswithanewlydiagnosedriskconditioningermany
AT galetzkawolfgang pneumococcalvaccinationcoverageinindividuals1659yearswithanewlydiagnosedriskconditioningermany
AT qizilbashnawab pneumococcalvaccinationcoverageinindividuals1659yearswithanewlydiagnosedriskconditioningermany
AT haeckldennis pneumococcalvaccinationcoverageinindividuals1659yearswithanewlydiagnosedriskconditioningermany
AT boellingertimo pneumococcalvaccinationcoverageinindividuals1659yearswithanewlydiagnosedriskconditioningermany
AT johnsonkellyd pneumococcalvaccinationcoverageinindividuals1659yearswithanewlydiagnosedriskconditioningermany
AT weissthomas pneumococcalvaccinationcoverageinindividuals1659yearswithanewlydiagnosedriskconditioningermany